Is Oruka Therapeutics, Inc. (ORKA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 23.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 23.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.2% / 33% | 94.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 23.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.2% / 33% | 94.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -24.7% | |
| Return on Assets (ROA) | -17.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$88M |
| Free Cash Flow | -$88M |
| Total Debt | $2M |
| Debt-to-Equity | 0.4 |
| Current Ratio | 22.4 |
| Total Assets | $489M |
Price & Trading
| Last Close | $45.46 |
| 50-Day MA | $35.35 |
| 200-Day MA | $24.56 |
| Avg Volume | 493K |
|
52-Week Range
$5.49
| |
About Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Oruka Therapeutics, Inc. (ORKA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Oruka Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Oruka Therapeutics, Inc.'s debt ratio?
Oruka Therapeutics, Inc.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.
What are Oruka Therapeutics, Inc.'s key financial metrics?
Oruka Therapeutics, Inc. has a market capitalization of $2.2B. Return on equity stands at -24.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.